| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 45 | 2026 | 755 | 8.310 |
Why?
|
| Transcription, Genetic | 32 | 2022 | 592 | 5.630 |
Why?
|
| Anemia, Sickle Cell | 25 | 2023 | 187 | 5.600 |
Why?
|
| Protein Phosphatase 1 | 23 | 2025 | 70 | 5.430 |
Why?
|
| Gene Expression Regulation, Viral | 15 | 2021 | 113 | 3.450 |
Why?
|
| Cyclin-Dependent Kinase 9 | 17 | 2021 | 37 | 3.280 |
Why?
|
| Virus Replication | 23 | 2025 | 318 | 2.700 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 17 | 2021 | 55 | 2.440 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2023 | 193 | 2.290 |
Why?
|
| Ebolavirus | 5 | 2025 | 49 | 2.270 |
Why?
|
| Cyclin-Dependent Kinase 2 | 12 | 2018 | 32 | 2.140 |
Why?
|
| HIV Infections | 18 | 2023 | 2586 | 2.110 |
Why?
|
| Phosphorylation | 28 | 2024 | 986 | 1.950 |
Why?
|
| Gene Products, tat | 12 | 2010 | 36 | 1.870 |
Why?
|
| Viral Proteins | 11 | 2025 | 190 | 1.780 |
Why?
|
| Phosphoprotein Phosphatases | 8 | 2010 | 49 | 1.690 |
Why?
|
| Nucleoproteins | 3 | 2025 | 15 | 1.670 |
Why?
|
| Antiviral Agents | 7 | 2022 | 195 | 1.480 |
Why?
|
| Sickle Cell Trait | 2 | 2022 | 19 | 1.440 |
Why?
|
| Iron Chelating Agents | 5 | 2017 | 21 | 1.250 |
Why?
|
| Urea | 5 | 2020 | 46 | 1.250 |
Why?
|
| Orosomucoid | 2 | 2020 | 12 | 1.200 |
Why?
|
| Anti-HIV Agents | 6 | 2017 | 486 | 1.140 |
Why?
|
| Indoles | 5 | 2020 | 187 | 1.120 |
Why?
|
| Humans | 97 | 2026 | 43102 | 1.110 |
Why?
|
| RNA Polymerase II | 7 | 2010 | 31 | 1.070 |
Why?
|
| Serine | 5 | 2018 | 79 | 1.060 |
Why?
|
| HIV Long Terminal Repeat | 6 | 2021 | 17 | 1.020 |
Why?
|
| Capsid | 2 | 2025 | 65 | 1.010 |
Why?
|
| Host-Pathogen Interactions | 8 | 2024 | 209 | 0.930 |
Why?
|
| Polycythemia | 9 | 2020 | 15 | 0.890 |
Why?
|
| Protein Binding | 13 | 2025 | 1082 | 0.870 |
Why?
|
| Cation Transport Proteins | 4 | 2012 | 35 | 0.860 |
Why?
|
| Macrophages | 7 | 2020 | 529 | 0.860 |
Why?
|
| Protein Multimerization | 1 | 2025 | 115 | 0.840 |
Why?
|
| RNA, Viral | 12 | 2024 | 321 | 0.800 |
Why?
|
| Cell Line | 17 | 2024 | 1410 | 0.780 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2021 | 19 | 0.700 |
Why?
|
| Iron | 10 | 2023 | 251 | 0.700 |
Why?
|
| Leukocytes, Mononuclear | 10 | 2023 | 247 | 0.640 |
Why?
|
| Quinolines | 1 | 2020 | 78 | 0.640 |
Why?
|
| Animals | 26 | 2026 | 16992 | 0.640 |
Why?
|
| Neutrophil Infiltration | 1 | 2020 | 28 | 0.630 |
Why?
|
| Lung | 2 | 2020 | 492 | 0.630 |
Why?
|
| Viral Core Proteins | 1 | 2019 | 12 | 0.620 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 257 | 0.610 |
Why?
|
| RNA Interference | 5 | 2019 | 247 | 0.580 |
Why?
|
| Ceruloplasmin | 1 | 2017 | 15 | 0.550 |
Why?
|
| Cyclin-Dependent Kinases | 5 | 2023 | 26 | 0.540 |
Why?
|
| Cyclin T | 5 | 2021 | 16 | 0.530 |
Why?
|
| Proviruses | 2 | 2015 | 35 | 0.530 |
Why?
|
| Small Molecule Libraries | 2 | 2021 | 62 | 0.530 |
Why?
|
| Cells, Cultured | 10 | 2018 | 1621 | 0.520 |
Why?
|
| Mass Spectrometry | 4 | 2018 | 280 | 0.500 |
Why?
|
| Mutation | 10 | 2018 | 1177 | 0.470 |
Why?
|
| Isoquinolines | 2 | 2015 | 55 | 0.470 |
Why?
|
| Mutant Proteins | 2 | 2012 | 51 | 0.460 |
Why?
|
| Virus Activation | 1 | 2015 | 38 | 0.460 |
Why?
|
| RNA-Binding Proteins | 3 | 2012 | 161 | 0.460 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2006 | 95 | 0.450 |
Why?
|
| Genes, Viral | 2 | 2012 | 61 | 0.440 |
Why?
|
| Sulfonamides | 1 | 2015 | 91 | 0.440 |
Why?
|
| Thiosemicarbazones | 2 | 2012 | 10 | 0.430 |
Why?
|
| Oxygen | 2 | 2020 | 218 | 0.430 |
Why?
|
| Mucins | 2 | 2026 | 73 | 0.420 |
Why?
|
| Virion | 4 | 2026 | 75 | 0.420 |
Why?
|
| Mice | 10 | 2023 | 6644 | 0.420 |
Why?
|
| I-kappa B Kinase | 1 | 2014 | 51 | 0.420 |
Why?
|
| Proteomics | 6 | 2024 | 378 | 0.410 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 7 | 2017 | 20 | 0.410 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2011 | 38 | 0.410 |
Why?
|
| Gene Expression | 6 | 2023 | 701 | 0.410 |
Why?
|
| Amino Acid Sequence | 7 | 2018 | 1180 | 0.410 |
Why?
|
| Hela Cells | 9 | 2012 | 376 | 0.410 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2024 | 863 | 0.400 |
Why?
|
| Adenovirus E4 Proteins | 1 | 2012 | 2 | 0.380 |
Why?
|
| CDC2-CDC28 Kinases | 2 | 2002 | 4 | 0.380 |
Why?
|
| Serpins | 1 | 2012 | 27 | 0.370 |
Why?
|
| Biocatalysis | 1 | 2012 | 30 | 0.370 |
Why?
|
| Nerve Growth Factors | 1 | 2012 | 34 | 0.370 |
Why?
|
| Hemolysis | 3 | 2023 | 60 | 0.370 |
Why?
|
| Vero Cells | 7 | 2024 | 112 | 0.370 |
Why?
|
| Eye Proteins | 1 | 2012 | 63 | 0.370 |
Why?
|
| Female | 25 | 2021 | 24698 | 0.340 |
Why?
|
| Endothelial Cells | 2 | 2023 | 329 | 0.340 |
Why?
|
| Rift Valley fever virus | 2 | 2024 | 9 | 0.330 |
Why?
|
| Endoribonucleases | 1 | 2010 | 25 | 0.330 |
Why?
|
| Male | 25 | 2021 | 23409 | 0.330 |
Why?
|
| RNA, Small Interfering | 5 | 2019 | 436 | 0.330 |
Why?
|
| Hydroxyurea | 3 | 2016 | 34 | 0.330 |
Why?
|
| Models, Molecular | 5 | 2018 | 876 | 0.320 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2006 | 4 | 0.310 |
Why?
|
| Early Diagnosis | 2 | 2021 | 68 | 0.310 |
Why?
|
| Down-Regulation | 2 | 2011 | 456 | 0.310 |
Why?
|
| Disease Progression | 3 | 2021 | 667 | 0.310 |
Why?
|
| Cell Nucleus | 3 | 2012 | 383 | 0.300 |
Why?
|
| Erythropoietin | 6 | 2016 | 38 | 0.290 |
Why?
|
| Mannose | 2 | 2026 | 32 | 0.280 |
Why?
|
| Inflammation | 5 | 2020 | 758 | 0.280 |
Why?
|
| Cytomegalovirus | 2 | 2024 | 45 | 0.270 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 665 | 0.270 |
Why?
|
| Benzoates | 1 | 2007 | 17 | 0.270 |
Why?
|
| Adult | 16 | 2023 | 13872 | 0.270 |
Why?
|
| Transcription Factors | 4 | 2019 | 735 | 0.270 |
Why?
|
| Cell Cycle Proteins | 2 | 2016 | 241 | 0.260 |
Why?
|
| Positive Transcriptional Elongation Factor B | 3 | 2015 | 15 | 0.260 |
Why?
|
| Middle Aged | 12 | 2023 | 12222 | 0.250 |
Why?
|
| Cell Survival | 5 | 2014 | 945 | 0.250 |
Why?
|
| Nucleosides | 1 | 2006 | 30 | 0.250 |
Why?
|
| Triazoles | 1 | 2007 | 102 | 0.250 |
Why?
|
| Hepacivirus | 1 | 2006 | 74 | 0.250 |
Why?
|
| Kidney | 2 | 2020 | 372 | 0.250 |
Why?
|
| Genome-Wide Association Study | 3 | 2024 | 423 | 0.250 |
Why?
|
| Promoter Regions, Genetic | 3 | 2005 | 526 | 0.240 |
Why?
|
| Young Adult | 8 | 2023 | 5080 | 0.240 |
Why?
|
| Tricuspid Valve Insufficiency | 2 | 2020 | 12 | 0.240 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2012 | 200 | 0.240 |
Why?
|
| Pyrimidines | 1 | 2006 | 139 | 0.230 |
Why?
|
| Molecular Sequence Data | 4 | 2012 | 1542 | 0.230 |
Why?
|
| Models, Biological | 4 | 2018 | 712 | 0.230 |
Why?
|
| Lipopolysaccharides | 2 | 2020 | 239 | 0.230 |
Why?
|
| Erythropoiesis | 3 | 2023 | 11 | 0.230 |
Why?
|
| Catalytic Domain | 2 | 2018 | 118 | 0.220 |
Why?
|
| Adolescent | 7 | 2023 | 6081 | 0.220 |
Why?
|
| Curcumin | 2 | 2017 | 118 | 0.220 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2017 | 88 | 0.220 |
Why?
|
| Cytomegalovirus Infections | 1 | 2024 | 28 | 0.220 |
Why?
|
| Protein Conformation | 2 | 2018 | 416 | 0.220 |
Why?
|
| Proteins | 2 | 2020 | 382 | 0.210 |
Why?
|
| Up-Regulation | 1 | 2006 | 536 | 0.210 |
Why?
|
| Alleles | 3 | 2020 | 352 | 0.210 |
Why?
|
| Telomere | 1 | 2024 | 59 | 0.210 |
Why?
|
| DNA-Binding Proteins | 3 | 2012 | 561 | 0.200 |
Why?
|
| Reticulocytes | 1 | 2023 | 9 | 0.200 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2023 | 10 | 0.200 |
Why?
|
| PPAR alpha | 1 | 2022 | 42 | 0.190 |
Why?
|
| Vascular Diseases | 2 | 2020 | 33 | 0.190 |
Why?
|
| Erythroid Precursor Cells | 2 | 2020 | 5 | 0.190 |
Why?
|
| Aged | 6 | 2021 | 8214 | 0.180 |
Why?
|
| Immunohistochemistry | 2 | 2020 | 934 | 0.180 |
Why?
|
| Fetal Hemoglobin | 2 | 2013 | 13 | 0.180 |
Why?
|
| T-Lymphocytes | 3 | 2015 | 386 | 0.180 |
Why?
|
| Protein Kinases | 1 | 2002 | 100 | 0.180 |
Why?
|
| Kringles | 1 | 2021 | 5 | 0.180 |
Why?
|
| Quantitative Trait Loci | 2 | 2020 | 88 | 0.180 |
Why?
|
| Immunoprecipitation | 4 | 2011 | 127 | 0.180 |
Why?
|
| Cytokines | 2 | 2020 | 678 | 0.170 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 216 | 0.170 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2021 | 59 | 0.170 |
Why?
|
| Prognosis | 2 | 2021 | 861 | 0.170 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 147 | 0.170 |
Why?
|
| Drug Stability | 2 | 2018 | 129 | 0.170 |
Why?
|
| Enzyme Activation | 2 | 2012 | 462 | 0.170 |
Why?
|
| Brain Ischemia | 1 | 2023 | 189 | 0.170 |
Why?
|
| Homozygote | 5 | 2013 | 77 | 0.170 |
Why?
|
| tau Proteins | 1 | 2021 | 186 | 0.160 |
Why?
|
| Viruses | 1 | 2020 | 39 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2019 | 279 | 0.160 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2020 | 24 | 0.160 |
Why?
|
| Immunophenotyping | 1 | 2020 | 57 | 0.160 |
Why?
|
| Macrophages, Peritoneal | 1 | 2020 | 23 | 0.160 |
Why?
|
| Gene Expression Regulation | 4 | 2024 | 1070 | 0.160 |
Why?
|
| NF-kappa B | 2 | 2015 | 358 | 0.160 |
Why?
|
| Cyclin E | 2 | 2014 | 14 | 0.160 |
Why?
|
| Nucleocapsid Proteins | 1 | 2019 | 12 | 0.160 |
Why?
|
| Organ Specificity | 1 | 2020 | 141 | 0.160 |
Why?
|
| Lymphopenia | 1 | 2019 | 17 | 0.150 |
Why?
|
| Ribonucleoproteins | 1 | 2019 | 31 | 0.150 |
Why?
|
| Viral Matrix Proteins | 1 | 2019 | 18 | 0.150 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2019 | 33 | 0.150 |
Why?
|
| Chiroptera | 1 | 2019 | 25 | 0.150 |
Why?
|
| Amino Acid Motifs | 2 | 2012 | 97 | 0.150 |
Why?
|
| Nuclear Proteins | 2 | 2012 | 333 | 0.150 |
Why?
|
| RNA, Messenger | 3 | 2014 | 1271 | 0.150 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2018 | 9 | 0.150 |
Why?
|
| Viral Envelope Proteins | 1 | 2019 | 91 | 0.150 |
Why?
|
| Marburgvirus | 1 | 2018 | 8 | 0.140 |
Why?
|
| Stroke | 1 | 2023 | 340 | 0.140 |
Why?
|
| Ferritins | 4 | 2020 | 63 | 0.140 |
Why?
|
| Encephalitis Virus, Venezuelan Equine | 1 | 2018 | 11 | 0.140 |
Why?
|
| eIF-2 Kinase | 1 | 2018 | 11 | 0.140 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 719 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2012 | 159 | 0.140 |
Why?
|
| Cytoplasmic Granules | 1 | 2018 | 9 | 0.140 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 2 | 2016 | 19 | 0.140 |
Why?
|
| Hemoglobinuria | 1 | 2018 | 4 | 0.140 |
Why?
|
| Bacteria | 1 | 2021 | 293 | 0.140 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2018 | 8 | 0.140 |
Why?
|
| Inclusion Bodies | 1 | 2018 | 34 | 0.140 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2018 | 17 | 0.140 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 29 | 0.140 |
Why?
|
| Ubiquitination | 1 | 2018 | 62 | 0.140 |
Why?
|
| Aminopyridines | 1 | 2018 | 26 | 0.140 |
Why?
|
| Monocytes | 2 | 2010 | 277 | 0.140 |
Why?
|
| Capsid Proteins | 1 | 2018 | 76 | 0.140 |
Why?
|
| Actins | 2 | 2011 | 164 | 0.140 |
Why?
|
| Cyclins | 2 | 2009 | 34 | 0.130 |
Why?
|
| Genome, Viral | 4 | 2024 | 119 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 189 | 0.130 |
Why?
|
| Pyridones | 1 | 2018 | 50 | 0.130 |
Why?
|
| Reverse Transcription | 2 | 2014 | 23 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2010 | 384 | 0.130 |
Why?
|
| Binding Sites | 3 | 2018 | 671 | 0.130 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2016 | 2 | 0.130 |
Why?
|
| Heme Oxygenase-1 | 2 | 2015 | 52 | 0.130 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIalpha Subunit | 1 | 2016 | 2 | 0.130 |
Why?
|
| Jurkat Cells | 4 | 2019 | 87 | 0.130 |
Why?
|
| Thrombospondin 1 | 1 | 2017 | 23 | 0.130 |
Why?
|
| Cell Proliferation | 4 | 2015 | 1455 | 0.120 |
Why?
|
| Transcriptional Activation | 3 | 2012 | 173 | 0.120 |
Why?
|
| Protein Phosphatase 2 | 2 | 2006 | 26 | 0.120 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 1596 | 0.120 |
Why?
|
| Thrombosis | 1 | 2017 | 81 | 0.120 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 263 | 0.120 |
Why?
|
| HL-60 Cells | 1 | 2015 | 33 | 0.120 |
Why?
|
| Apolipoprotein B-100 | 1 | 2015 | 7 | 0.120 |
Why?
|
| Protein Transport | 2 | 2016 | 296 | 0.120 |
Why?
|
| Germ-Line Mutation | 2 | 2017 | 75 | 0.120 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2015 | 57 | 0.110 |
Why?
|
| Virus Latency | 1 | 2015 | 49 | 0.110 |
Why?
|
| Zanthoxylum | 1 | 2015 | 4 | 0.110 |
Why?
|
| Drug Design | 1 | 2017 | 186 | 0.110 |
Why?
|
| Genotype | 3 | 2013 | 800 | 0.110 |
Why?
|
| Hypertension, Pulmonary | 2 | 2014 | 78 | 0.110 |
Why?
|
| DNA Replication | 1 | 2016 | 148 | 0.110 |
Why?
|
| Receptors, Interferon | 1 | 2014 | 14 | 0.110 |
Why?
|
| Cyclin A | 1 | 2014 | 4 | 0.110 |
Why?
|
| HIV Envelope Protein gp120 | 2 | 2026 | 54 | 0.110 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2014 | 17 | 0.110 |
Why?
|
| Antisickling Agents | 2 | 2016 | 14 | 0.110 |
Why?
|
| Molecular Weight | 1 | 2014 | 168 | 0.110 |
Why?
|
| Purines | 2 | 2012 | 40 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 56 | 0.110 |
Why?
|
| Transcription Factor RelA | 1 | 2014 | 42 | 0.110 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2012 | 197 | 0.110 |
Why?
|
| Genetic Markers | 1 | 2014 | 150 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2014 | 12 | 0.110 |
Why?
|
| Mice, Knockout | 2 | 2014 | 1035 | 0.110 |
Why?
|
| COS Cells | 2 | 2005 | 68 | 0.110 |
Why?
|
| Antibodies, Neutralizing | 2 | 2026 | 127 | 0.100 |
Why?
|
| Streptomycin | 1 | 2013 | 4 | 0.100 |
Why?
|
| Child | 6 | 2023 | 3443 | 0.100 |
Why?
|
| Glutathione Transferase | 2 | 2005 | 90 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2013 | 12 | 0.100 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2013 | 31 | 0.100 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2013 | 465 | 0.100 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2013 | 20 | 0.100 |
Why?
|
| Transfection | 3 | 2015 | 532 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 2 | 2012 | 423 | 0.100 |
Why?
|
| Plasmids | 2 | 2005 | 244 | 0.100 |
Why?
|
| Case-Control Studies | 4 | 2021 | 1285 | 0.100 |
Why?
|
| Receptors, Chemokine | 1 | 2013 | 72 | 0.100 |
Why?
|
| Macrophage Activation | 1 | 2013 | 61 | 0.100 |
Why?
|
| Blood Transfusion | 1 | 2012 | 31 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 41 | 0.100 |
Why?
|
| Overweight | 1 | 2015 | 249 | 0.100 |
Why?
|
| Culture Media, Conditioned | 1 | 2012 | 49 | 0.100 |
Why?
|
| Chemokines | 1 | 2013 | 96 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2013 | 91 | 0.090 |
Why?
|
| Intracellular Space | 1 | 2012 | 37 | 0.090 |
Why?
|
| Hepatitis B | 1 | 2012 | 41 | 0.090 |
Why?
|
| Gene Frequency | 1 | 2012 | 206 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 80 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 1081 | 0.090 |
Why?
|
| Gene Silencing | 1 | 2012 | 154 | 0.090 |
Why?
|
| Plant Extracts | 1 | 2015 | 302 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2015 | 1124 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2012 | 296 | 0.090 |
Why?
|
| Pyridines | 1 | 2012 | 139 | 0.090 |
Why?
|
| Adenosine Triphosphate | 1 | 2012 | 206 | 0.090 |
Why?
|
| Peptide Mapping | 1 | 2011 | 20 | 0.090 |
Why?
|
| Blackwater Fever | 1 | 2011 | 1 | 0.090 |
Why?
|
| Proteome | 1 | 2012 | 152 | 0.090 |
Why?
|
| Point Mutation | 2 | 2009 | 98 | 0.080 |
Why?
|
| Threonine | 1 | 2010 | 24 | 0.080 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2011 | 65 | 0.080 |
Why?
|
| Child, Preschool | 5 | 2020 | 1546 | 0.080 |
Why?
|
| Virus Integration | 2 | 2012 | 65 | 0.080 |
Why?
|
| Rift Valley Fever | 2 | 2024 | 8 | 0.080 |
Why?
|
| Blotting, Western | 3 | 2012 | 883 | 0.080 |
Why?
|
| Malaria, Cerebral | 1 | 2011 | 30 | 0.080 |
Why?
|
| Hepatitis C | 1 | 2012 | 139 | 0.080 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 2676 | 0.080 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2010 | 9 | 0.080 |
Why?
|
| Rabbits | 1 | 2010 | 278 | 0.080 |
Why?
|
| Russia | 4 | 2013 | 29 | 0.080 |
Why?
|
| Biological Transport | 1 | 2010 | 204 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 652 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 432 | 0.080 |
Why?
|
| Malaria, Falciparum | 1 | 2011 | 90 | 0.080 |
Why?
|
| Sp1 Transcription Factor | 1 | 2009 | 46 | 0.080 |
Why?
|
| Protein Interaction Mapping | 2 | 2024 | 65 | 0.080 |
Why?
|
| Kinetics | 2 | 2013 | 695 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2009 | 183 | 0.070 |
Why?
|
| Peptides | 1 | 2012 | 372 | 0.070 |
Why?
|
| Iron, Dietary | 1 | 2008 | 13 | 0.070 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 595 | 0.070 |
Why?
|
| CDC2 Protein Kinase | 1 | 2008 | 19 | 0.070 |
Why?
|
| RNA Splicing | 1 | 2008 | 41 | 0.070 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2008 | 12 | 0.070 |
Why?
|
| Homocysteine | 1 | 2008 | 21 | 0.070 |
Why?
|
| Dipeptides | 1 | 2008 | 31 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2020 | 1600 | 0.070 |
Why?
|
| Isoniazid | 1 | 2007 | 6 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 518 | 0.060 |
Why?
|
| Gene Products, rev | 1 | 2006 | 4 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2023 | 213 | 0.060 |
Why?
|
| Karyopherins | 1 | 2006 | 7 | 0.060 |
Why?
|
| Glutathione | 1 | 2008 | 171 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 760 | 0.060 |
Why?
|
| RNA Helicases | 1 | 2006 | 19 | 0.060 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2006 | 31 | 0.060 |
Why?
|
| Chromatography, Liquid | 2 | 2021 | 182 | 0.060 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2006 | 66 | 0.060 |
Why?
|
| Genes, Reporter | 1 | 2006 | 148 | 0.060 |
Why?
|
| DNA-Directed RNA Polymerases | 2 | 2018 | 22 | 0.060 |
Why?
|
| Receptors, Transferrin | 1 | 2006 | 15 | 0.060 |
Why?
|
| Systole | 1 | 2006 | 67 | 0.060 |
Why?
|
| Pulmonary Artery | 1 | 2006 | 32 | 0.060 |
Why?
|
| Endothelin-1 | 1 | 2006 | 57 | 0.060 |
Why?
|
| Phosphorylase a | 1 | 2005 | 2 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2015 | 1759 | 0.060 |
Why?
|
| Biotinylation | 1 | 2005 | 12 | 0.060 |
Why?
|
| Genes, tat | 1 | 2005 | 8 | 0.060 |
Why?
|
| beta-Galactosidase | 1 | 2005 | 37 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1067 | 0.060 |
Why?
|
| Phenylalanine | 1 | 2005 | 25 | 0.060 |
Why?
|
| Valine | 1 | 2005 | 29 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2005 | 44 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2007 | 139 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2006 | 219 | 0.060 |
Why?
|
| Apoptosis | 3 | 2014 | 1568 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1092 | 0.060 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 99 | 0.060 |
Why?
|
| Swine | 1 | 2026 | 212 | 0.060 |
Why?
|
| Cyclin H | 1 | 2005 | 1 | 0.060 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2005 | 51 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2026 | 388 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 256 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2007 | 403 | 0.050 |
Why?
|
| Casein Kinase Ialpha | 1 | 2024 | 2 | 0.050 |
Why?
|
| K562 Cells | 1 | 2024 | 32 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2007 | 408 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2018 | 863 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 2853 | 0.050 |
Why?
|
| HIV Antibodies | 1 | 2023 | 24 | 0.050 |
Why?
|
| Neutrophils | 2 | 2020 | 145 | 0.050 |
Why?
|
| Erythroblasts | 1 | 2023 | 2 | 0.050 |
Why?
|
| HIV Reverse Transcriptase | 2 | 2015 | 35 | 0.050 |
Why?
|
| Dependovirus | 1 | 2003 | 18 | 0.050 |
Why?
|
| Glycosylation | 1 | 2023 | 113 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2008 | 609 | 0.050 |
Why?
|
| Brazil | 1 | 2023 | 84 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2003 | 165 | 0.050 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2002 | 9 | 0.050 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 196 | 0.050 |
Why?
|
| Cell Hypoxia | 2 | 2014 | 60 | 0.040 |
Why?
|
| Infant | 3 | 2011 | 1175 | 0.040 |
Why?
|
| Hemoglobins | 2 | 2015 | 113 | 0.040 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2020 | 7 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2002 | 281 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 69 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2020 | 72 | 0.040 |
Why?
|
| Pulmonary Fibrosis | 1 | 2020 | 38 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 116 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2023 | 2157 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2019 | 48 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 241 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 355 | 0.040 |
Why?
|
| Hospitals, Special | 1 | 2018 | 3 | 0.040 |
Why?
|
| Congo | 1 | 2018 | 3 | 0.040 |
Why?
|
| Patient Care | 1 | 2018 | 31 | 0.040 |
Why?
|
| Autophagy | 1 | 2019 | 140 | 0.040 |
Why?
|
| Sequence Homology | 1 | 2018 | 35 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2006 | 1019 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 3156 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2018 | 207 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2020 | 638 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 118 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2016 | 56 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2015 | 52 | 0.030 |
Why?
|
| Half-Life | 1 | 2015 | 63 | 0.030 |
Why?
|
| United States | 2 | 2020 | 5205 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 518 | 0.030 |
Why?
|
| Virulence | 1 | 2016 | 246 | 0.030 |
Why?
|
| Triglycerides | 1 | 2015 | 147 | 0.030 |
Why?
|
| Phytotherapy | 1 | 2015 | 75 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1612 | 0.030 |
Why?
|
| Streptomyces | 1 | 2013 | 22 | 0.030 |
Why?
|
| Phlebotomy | 1 | 2013 | 5 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1078 | 0.030 |
Why?
|
| Cholesterol | 1 | 2015 | 232 | 0.030 |
Why?
|
| Heterozygote | 1 | 2013 | 110 | 0.030 |
Why?
|
| Protein Stability | 1 | 2013 | 48 | 0.030 |
Why?
|
| Brain | 1 | 2021 | 1472 | 0.030 |
Why?
|
| Croatia | 1 | 2013 | 4 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 166 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2013 | 90 | 0.020 |
Why?
|
| Mortality | 1 | 2014 | 175 | 0.020 |
Why?
|
| Granulocytes | 1 | 2013 | 26 | 0.020 |
Why?
|
| Pedigree | 1 | 2013 | 94 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 95 | 0.020 |
Why?
|
| Family Health | 1 | 2013 | 55 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2013 | 245 | 0.020 |
Why?
|
| Virus Release | 1 | 2012 | 9 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 704 | 0.020 |
Why?
|
| Plant Roots | 1 | 2015 | 180 | 0.020 |
Why?
|
| Isomerism | 1 | 2012 | 64 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2012 | 64 | 0.020 |
Why?
|
| Haplotypes | 1 | 2013 | 197 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2013 | 171 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2012 | 57 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 437 | 0.020 |
Why?
|
| Virus Assembly | 1 | 2012 | 44 | 0.020 |
Why?
|
| Limit of Detection | 1 | 2012 | 94 | 0.020 |
Why?
|
| Electroporation | 1 | 2011 | 21 | 0.020 |
Why?
|
| Insulin | 1 | 2013 | 258 | 0.020 |
Why?
|
| Nucleosomes | 1 | 2011 | 30 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2013 | 389 | 0.020 |
Why?
|
| Base Sequence | 1 | 2013 | 983 | 0.020 |
Why?
|
| Zambia | 1 | 2011 | 50 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2012 | 570 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2013 | 460 | 0.020 |
Why?
|
| Africa | 1 | 2010 | 82 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 780 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 411 | 0.020 |
Why?
|
| Chromatin | 1 | 2011 | 186 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 346 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 737 | 0.020 |
Why?
|
| Plasmodium falciparum | 1 | 2011 | 144 | 0.020 |
Why?
|
| CD4-CD8 Ratio | 1 | 2009 | 29 | 0.020 |
Why?
|
| Interleukins | 1 | 2009 | 40 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2008 | 16 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2008 | 27 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 92 | 0.020 |
Why?
|
| Hemeproteins | 1 | 2008 | 15 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 638 | 0.020 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2008 | 9 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2008 | 195 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 490 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2007 | 10 | 0.020 |
Why?
|
| Health Surveys | 1 | 2008 | 405 | 0.020 |
Why?
|
| Altitude | 1 | 2006 | 10 | 0.020 |
Why?
|
| Reticulocyte Count | 1 | 2006 | 3 | 0.020 |
Why?
|
| Zimbabwe | 1 | 2006 | 5 | 0.020 |
Why?
|
| Urban Population | 1 | 2008 | 374 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 211 | 0.010 |
Why?
|
| Piperidines | 1 | 2006 | 83 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2006 | 165 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2006 | 185 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2006 | 167 | 0.010 |
Why?
|
| Flavonoids | 1 | 2006 | 100 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2008 | 666 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 3994 | 0.010 |
Why?
|